UTHR Stock Risk & Deep Value Analysis
United Therapeutics Corp
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About UTHR Stock
We analyzed United Therapeutics Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran UTHR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
UTHR Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the failure or significant delay of United Therapeutics' ambitious xenotransplantation and regenerative medicine programs, particularly the long path to commercialization for whole organ manufacturing. While the core business is robust, its value is largely priced in; the 10x growth potential hinges on these high-risk, long-duration projects.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Significant insider selling by CFO and CEO (though pre-planned) could indicate a perception of limited near-term upside.
- ⚠
The very long-term, speculative nature of the xenotransplantation pipeline, with significant capital outlay required before broad commercialization.
Upcoming Risk Events
- 📅
Disappointing Q1 2026 earnings or guidance
- 📅
Negative clinical trial results for pipeline assets
- 📅
Unexpected regulatory delays or setbacks
When to Reconsider
- 🚪
Exit if key xenotransplantation programs face major clinical trial failures or are discontinued.
- 🚪
Sell if core pulmonary hypertension product sales begin to decline significantly due to new competition.
- 🚪
Exit if quarterly EPS falls below consensus estimates for two consecutive quarters, coupled with negative guidance.
Unlock UTHR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does United Therapeutics Corp (UTHR) Do?
Market Cap
$25.83B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Visit United Therapeutics Corp WebsiteInvestment Thesis
United Therapeutics offers a compelling investment opportunity driven by a robust, cash-generating core business in rare pulmonary diseases, which is expanding into new indications like IPF. This strong foundation funds a highly ambitious, long-term regenerative medicine and xenotransplantation pipeline that could fundamentally transform organ supply. While the 10x potential within 3-5 years is a stretch given its current large-cap status and the timelines involved for broad xenotransplantation, continued strong execution in both core and pipeline offers significant growth potential.
Is UTHR Stock Undervalued?
Unlock the full AI analysis for UTHR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
UTHR Price Targets & Strategy
12-Month Target
$650.00
Bull Case
$720.00
Bear Case
$500.00
Valuation Basis
Based on 24x forward P/E applied to estimated annualized FY26 EPS of $27.08 (4x Q1 consensus of $6.77).
Entry Strategy
Consider dollar-cost averaging on dips towards the $550-$570 range, which has shown recent support. Look for consolidation after next earnings.
Exit Strategy
Take profit on 25-50% of position above $650, reassess after xenotransplantation milestones. Implement a stop-loss at $500 to protect capital.
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is UTHR Financially Healthy?
Valuation
P/E Ratio
19.35
Profitability
Gross Margin
87.92%
Operating Margin
46.89%
Net Margin
41.94%
Return on Equity
19.30%
Revenue Growth
10.61%
EPS
$27.90
Balance Sheet
Current Ratio
6.60
Quick Ratio
6.28
Total Debt
$5.20B
Cash & Equivalents
$5.20B
Cash Flow
Operating Cash Flow
$5.20B
Free Cash Flow
$5.20B
EBITDA
$5.20B
Other
Beta (Volatility)
0.63
Does UTHR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is durable due to strong patent protection and orphan drug designations for existing therapies. Its early lead and vast R&D investment in xenotransplantation, coupled with regulatory designations like RMAT for miroliverELAP, are expanding its moat into future, highly complex medical fields.
Moat Erosion Risks
- •Patent expirations on key drugs (though some have long runways).
- •Failure to translate early-stage regenerative medicine research into commercially viable products.
- •Emergence of superior therapies or competing technologies in its core or future markets.
UTHR Competitive Moat Analysis
Sign up to see competitive advantages
UTHR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish - driven by excitement around pipeline advancements but tempered by large market cap and long-term nature of moonshot projects.
Institutional Sentiment
Positive - evidenced by recent analyst upgrades (Cantor Fitzgerald, TD Cowen, Wells Fargo) and raised price targets.
Insider Activity (Form 4)
CFO James Edgemond sold 10,000 shares for ~$5.76M-$5.82M on April 16, 2026, after exercising options. CEO Martine Rothblatt sold 9,500 shares for ~$5.45M-$5.52M around April 17, 2026, after exercising options. Both sales were under Rule 10b5-1 plans.
Options Flow
Normal options activity observed; no significant unusual put or call activity indicating extreme institutional positioning was reported.
Earnings Intelligence
Next Earnings
2026-04-29
Surprise Probability
Medium - historically UTHR has a mixed record of EPS beats and revenue misses; prior quarter was an EPS beat with a revenue miss.
Historical Earnings Pattern
Stock reaction to earnings has been mixed; often positive on strong EPS beats or positive pipeline news, but can be sensitive to revenue misses or cautious guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ (Actelion unit)
Market Share Trend
Gaining - particularly with the expansion of Tyvaso into new indications like IPF, which will significantly grow its market share in pulmonary hypertension/fibrosis.
Valuation vs Peers
UTHR trades at a slight premium to established pharma peers on a P/E basis, reflecting its strong growth in rare diseases and high-potential R&D pipeline.
Competitive Advantages
- •Strong intellectual property and regulatory exclusivity for its rare disease treatments.
- •First-mover advantage and significant investment in xenotransplantation and regenerative medicine.
- •Established commercial infrastructure in niche pulmonary markets.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive UTHR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Announcement (April 29, 2026)
- •Detailed Phase 1 miroliverELAP data H2 2026
Medium-Term (6-18 months)
- •Potential FDA filing/approval for Tyvaso in IPF
- •Progression of miroliverELAP into later-stage clinical trials
- •Strategic partnerships or further pipeline advancements in regenerative medicine
Long-Term (18+ months)
- •Advancements in xenotransplantation toward human clinical trials for broader organ types
- •Market leadership in regenerative medicine for organ failure
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for UTHR?
- ✓
Accelerated timelines or successful Phase 2/3 trials for miroliverELAP or other regenerative medicine assets.
- ✓
Sustained double-digit revenue growth in the core pulmonary franchise.
- ✓
Positive commentary on xenotransplantation progress from regulatory bodies.
Bull Case Analysis
See what could go right with Premium
Competing with UTHR
See how United Therapeutics Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
United Therapeutics Corp UTHR | $25.8B | 5.5 | 19.4 | $5.2B | 41.9% | 10.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How United Therapeutics Corp Makes Money
United Therapeutics develops and commercializes innovative medicines for patients with life-threatening diseases, primarily focusing on rare pulmonary conditions like pulmonary hypertension and pulmonary fibrosis. It generates revenue from selling these pharmaceutical products. In parallel, the company has a groundbreaking research and development division dedicated to creating an unlimited supply of transplantable organs through xenotransplantation and regenerative medicine, which represents its long-term, high-risk, high-reward growth strategy. Essentially, it uses the profits from its established drug business to fund the futuristic quest for manufactured organs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for United Therapeutics Corp (UTHR)?
As of April 18, 2026, United Therapeutics Corp has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of United Therapeutics Corp?
United Therapeutics Corp's market capitalization is approximately $25.8B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does United Therapeutics Corp use?
UTHR is the ticker symbol for United Therapeutics Corp. The company trades on the NMS.
What is the risk level for UTHR stock?
Our analysis rates United Therapeutics Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of UTHR?
United Therapeutics Corp currently has a price-to-earnings (P/E) ratio of 19.4. This is in line with broader market averages.
Is United Therapeutics Corp's revenue growing?
United Therapeutics Corp has reported revenue growth of 10.6%. The company is showing strong top-line momentum.
Is UTHR stock profitable?
United Therapeutics Corp has a profit margin of 41.9%. This indicates strong profitability.
How often is the UTHR DVR analysis updated?
Our AI-powered analysis of United Therapeutics Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 18, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for UTHR (United Therapeutics Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.